Galux and Woojung Bio Sign Strategic Partnership for AI-Based Therapeutic Development

Establishing a Rapid Non-Clinical Validation System for AI-Based Drug Candidates

Woojung Bio announced on September 30 that it has entered into a strategic partnership with Galux, an artificial intelligence (AI)-based drug development company.

Song Mooyoung, head of the Gallax division (left), and Yoon Jabin, director of Woojung Bio (right), are taking a commemorative photo after signing a strategic business agreement on the 29th for AI-based drug development. Gallax

Woojung Bio has recently been collaborating with various biotech companies through open innovation projects, striving to build advanced non-clinical CRO services that incorporate a range of technologies, including AI. This partnership also aims to accelerate the development of antibody therapeutics by combining Woojung Bio’s non-clinical expertise with Galux’s AI-based drug development platform.

Through this agreement, the two companies will establish a research and development collaboration system to continuously improve the accuracy of AI drug development. Their joint efforts will include: building a rapid non-clinical validation system for AI-based drug candidates; cooperating on the discovery of new targets and the joint research and development of innovative drugs; sharing information and networks; and conducting joint research and development utilizing each company’s infrastructure.

Galux possesses de novo antibody design technology, which enables the design of entirely new antibodies from scratch, regardless of therapeutic format, based on its proprietary platform ‘Galux Design’ that uniquely integrates AI and physicochemical principles. Unlike traditional methods such as biological immune responses or antibody library screening, de novo antibody design allows for precise consideration of molecular characteristics from the design stage, greatly enhancing both the efficiency and success rate of drug development.

Galux CEO Seok Chaok stated, “Galux is laying the groundwork for translating technological possibilities into real therapeutics by designing entirely new antibodies using AI and validating them through actual non-clinical studies. This collaboration with Woojung Bio will be a key turning point, combining Galux’s design capabilities with Woojung Bio’s non-clinical validation expertise to connect AI drug development to clinical trials more quickly and reliably.”

Woojung Bio CEO Chun Heejung said, “With this agreement, we will do our utmost to establish Woojung Bio’s proprietary non-clinical services. To this end, we will also actively expand open innovation projects with various companies.”

This content was produced with the assistance of AI translation services.